SOURCE: Bio-Rad Laboratories

July 17, 2007 08:00 ET

Bio-Rad Signs Two Multi-Year Agreements With Quest Diagnostics

HERCULES, CA--(Marketwire - July 17, 2007) - Bio-Rad Laboratories (AMEX: BIO) and (AMEX: BIOb), Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that the company has signed two multi-year agreements with Quest Diagnostics Incorporated (NYSE: DGX) to place BioPlex® 2200 systems and autoimmune test reagents as well as Bio-Rad's HIV-1/HIV-2 PLUS O EIA assay, which allows Quest Diagnostics to detect HIV-1 and HIV-2 in their network of reference laboratories nationwide. Terms of the agreements were not disclosed.

The BioPlex 2200 system is the first and only fully-automated random access testing system employing multiplex technology to simultaneously generate multiple results from a single small patient sample. Introduced last year, the BioPlex 2200 system brings the benefits of full automation and random access capability to labor intensive specialty testing areas such as autoimmune and serology. In early April, Bio-Rad announced that it had released Epstein Barr Virus kits to run on the BioPlex 2200 system and that it has more than 15 other multiplex reagent kits in development for the system.

"We are excited to work with Quest Diagnostics and are confident that the BioPlex 2200 system will serve them well by enhancing their already outstanding reputation for high quality testing and excellent service to their clients," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Quest will be the first national reference lab in the country to offer the BioPlex ANA Screen. As a result, clinicians and patients will benefit from broad access to this innovative technology."

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com.

Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.

Contact Information

  • For more information contact:
    Tina Cuccia
    Corporate Communications Manager
    Bio-Rad Laboratories, Inc.
    510-724-7000
    Email Contact